These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38671586)

  • 41. Waldenstrom macroglobulinaemia treated with sequential hemibody irradiation.
    Jacobs P; Wood L; le Roux I; Prior C; King HS
    J Clin Apher; 1987; 3(3):181-4. PubMed ID: 3104317
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Diffuse large cell lymphoma and colon adenocarcinoma in patient with Waldenström's macroglobulinaemia].
    Radojković M; Ristić S; Colović N; Cemerikić-Martinović V; Colović M
    Srp Arh Celok Lek; 2011; 139(1-2):95-8. PubMed ID: 21568089
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Simvastatin, a potent HMG-CoA reductase inhibitor, inhibits the proliferation of human and bovine endothelial cells in vitro.
    Sato I; Ma L; Ikeda M; Morita I; Murota S
    J Atheroscler Thromb; 1998; 4(3):102-6. PubMed ID: 9730140
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.
    Neuvonen PJ; Kantola T; Kivistö KT
    Clin Pharmacol Ther; 1998 Mar; 63(3):332-41. PubMed ID: 9542477
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The HMG-CoA reductase inhibitor simvastatin suppresses human testicular testosterone synthesis in vitro by a selective inhibitory effect on 17-ketosteroid-oxidoreductase enzyme activity.
    Smals AG; Weusten JJ; Benraad TJ; Kloppenborg PW
    J Steroid Biochem Mol Biol; 1991 Apr; 38(4):465-8. PubMed ID: 2031860
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A case of 'acute' Waldenström macroglobulinaemia.
    Malý J; Tichý M; Bláha M; Siroký O; Vanásek J; Jebavý L; Hrncír Z
    Haematologia (Budap); 1984; 17(1):125-30. PubMed ID: 6427068
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Modulation of radiosensitivity of DU145 prostate carcinoma cells by simvastatin.
    Korte V; Gademann G; Gawish A; Ochel HJ
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4509-4514. PubMed ID: 36127484
    [TBL] [Abstract][Full Text] [Related]  

  • 48. IAF, QGF, and QDF Peptides Exhibit Cholesterol-Lowering Activity through a Statin-like HMG-CoA Reductase Regulation Mechanism: In Silico and In Vitro Approach.
    Silva M; Philadelpho B; Santos J; Souza V; Souza C; Santiago V; Silva J; Souza C; Azeredo F; Castilho M; Cilli E; Ferreira E
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681729
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Direct inhibitory effects of simvastatin on matrix accumulation in cultured murine mesangial cells.
    Nogaki F; Muso E; Yashiro M; Kasuno K; Kamata T; Ono T; Sasayama S
    Kidney Int Suppl; 1999 Jul; 71():S198-201. PubMed ID: 10412775
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The pathology and genetic background of lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia].
    Timár B
    Magy Onkol; 2017 Mar; 61(1):6-11. PubMed ID: 28273183
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.
    Laufs U; La Fata V; Plutzky J; Liao JK
    Circulation; 1998 Mar; 97(12):1129-35. PubMed ID: 9537338
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats.
    Giusti-Paiva A; Martinez MR; Felix JV; da Rocha MJ; Carnio EC; Elias LL; Antunes-Rodrigues J
    Shock; 2004 Mar; 21(3):271-5. PubMed ID: 14770041
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders.
    Varettoni M; Zibellini S; Boveri E; Klersy C; Candido C; Rattotti S; Ferretti VV; Defrancesco I; Mangiacavalli S; Nizzoli ME; Flospergher E; Zerbi C; Bergamini F; Benvenuti P; Brociner M; Merati G; Paulli M; Arcaini L
    Br J Haematol; 2019 Nov; 187(4):441-446. PubMed ID: 31276195
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia.
    Castillo JJ; Garcia-Sanz R; Hatjiharissi E; Kyle RA; Leleu X; McMaster M; Merlini G; Minnema MC; Morra E; Owen RG; Poulain S; Stone MJ; Tam C; Varettoni M; Dimopoulos MA; Treon SP; Kastritis E
    Br J Haematol; 2016 Oct; 175(1):77-86. PubMed ID: 27378193
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin.
    Cheng H; Rogers JD; Sweany AE; Dobrinska MR; Stein EA; Tate AC; Amin RD; Quan H
    Pharm Res; 1992 Dec; 9(12):1629-33. PubMed ID: 1488408
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells.
    Kwak B; Mulhaupt F; Veillard N; Pelli G; Mach F
    Swiss Med Wkly; 2001 Jan; 131(3-4):41-6. PubMed ID: 11219190
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemia.
    Castillo JJ; Gustine JN; Meid K; Dubeau T; Severns P; Xu L; Yang G; Hunter ZR; Treon SP
    Br J Haematol; 2019 Mar; 184(6):1011-1014. PubMed ID: 29532913
    [No Abstract]   [Full Text] [Related]  

  • 58. Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
    Talaulikar D; Joshua D; Ho PJ; Gibson J; Quach H; Gibbs S; Ling S; Ward C; Augustson BM; Trotman J; Harrison SJ; Tam CS;
    Intern Med J; 2023 Apr; 53(4):599-609. PubMed ID: 36441109
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunobullous dermatosis associated with Waldenström macroglobulinaemia treated with rituximab.
    Chattopadhyay M; Rytina E; Dada M; Bhogal BS; Groves R; Handfield-Jones S
    Clin Exp Dermatol; 2013 Dec; 38(8):866-9. PubMed ID: 23782150
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.